Technical Analysis for DERM - Dermira, Inc.

Grade Last Price % Change Price Change
grade C 7.62 1.20% 0.09
DERM closed up 1.2 percent on Friday, November 15, 2019, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical DERM trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Calm After Storm Range Contraction -5.81%
Upper Bollinger Band Walk Strength -5.81%
Wide Bands Range Expansion -5.81%
Calm After Storm Range Contraction -5.81%
Upper Bollinger Band Walk Strength -5.81%

Older signals for DERM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company's late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Medicine Biopharmaceutical Psoriasis Acne Immunosuppressants Dermatology Skin Cutaneous Conditions Hyperhidrosis Inflammatory Skin Diseases Treatment Of Inflammatory Skin Diseases
Is DERM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.48
52 Week Low 5.25
Average Volume 1,277,436
200-Day Moving Average 8.9807
50-Day Moving Average 7.0973
20-Day Moving Average 7.232
10-Day Moving Average 7.5505
Average True Range 0.6384
ADX 28.43
+DI 31.8598
-DI 19.669
Chandelier Exit (Long, 3 ATRs ) 7.3548
Chandelier Exit (Short, 3 ATRs ) 7.4052
Upper Bollinger Band 8.2839
Lower Bollinger Band 6.1801
Percent B (%b) 0.68
BandWidth 29.090155
MACD Line 0.2887
MACD Signal Line 0.1936
MACD Histogram 0.0951
Fundamentals Value
Market Cap 318.24 Million
Num Shares 41.8 Million
EPS -2.70
Price-to-Earnings (P/E) Ratio -2.82
Price-to-Sales 43.67
Price-to-Book 2.90
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.05
Resistance 3 (R3) 8.04 7.88 7.98
Resistance 2 (R2) 7.88 7.77 7.89 7.96
Resistance 1 (R1) 7.75 7.70 7.81 7.76 7.93
Pivot Point 7.59 7.59 7.62 7.60 7.59
Support 1 (S1) 7.46 7.48 7.53 7.48 7.31
Support 2 (S2) 7.30 7.41 7.31 7.28
Support 3 (S3) 7.17 7.30 7.26
Support 4 (S4) 7.19